ZA201904494B - Anti¿tgf¿beta antibodies and their use - Google Patents

Anti¿tgf¿beta antibodies and their use

Info

Publication number
ZA201904494B
ZA201904494B ZA2019/04494A ZA201904494A ZA201904494B ZA 201904494 B ZA201904494 B ZA 201904494B ZA 2019/04494 A ZA2019/04494 A ZA 2019/04494A ZA 201904494 A ZA201904494 A ZA 201904494A ZA 201904494 B ZA201904494 B ZA 201904494B
Authority
ZA
South Africa
Prior art keywords
tgf
beta antibodies
antibodies
beta
Prior art date
Application number
ZA2019/04494A
Other languages
English (en)
Inventor
Gary Shapiro
Kevin Browen
Patrick Finn
Richard C Gregory
Rao Koduri
Feng Liu
Natalia Malkova
Parminder Mankoo
Jack R Pollard
Huawei Qiu
Joachim Theilhaber
Christopher Winter
Marcella Yu
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2018/000088 external-priority patent/WO2018134681A1/en
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ZA201904494B publication Critical patent/ZA201904494B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA2019/04494A 2017-01-20 2019-07-09 Anti¿tgf¿beta antibodies and their use ZA201904494B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448800P 2017-01-20 2017-01-20
EP17305061 2017-01-20
PCT/IB2018/000088 WO2018134681A1 (en) 2017-01-20 2018-01-19 Anti-tgf-beta antibodies and their use

Publications (1)

Publication Number Publication Date
ZA201904494B true ZA201904494B (en) 2020-12-23

Family

ID=61656071

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/04494A ZA201904494B (en) 2017-01-20 2019-07-09 Anti¿tgf¿beta antibodies and their use

Country Status (22)

Country Link
US (4) US10766955B2 (https=)
JP (4) JP7213186B2 (https=)
CN (2) CN117417939A (https=)
AU (2) AU2018209391B2 (https=)
BR (1) BR112019014787A2 (https=)
CA (1) CA3050845A1 (https=)
CL (1) CL2019002011A1 (https=)
CO (1) CO2019008946A2 (https=)
CR (1) CR20190375A (https=)
DO (1) DOP2019000191A (https=)
EC (1) ECSP19059553A (https=)
IL (3) IL268112B2 (https=)
MA (1) MA47311A (https=)
MX (2) MX2019008551A (https=)
MY (1) MY200751A (https=)
NZ (1) NZ796440A (https=)
PE (1) PE20200734A1 (https=)
PH (1) PH12019501635A1 (https=)
SG (1) SG11201906660TA (https=)
TW (3) TW202506185A (https=)
UY (1) UY37575A (https=)
ZA (1) ZA201904494B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI788321B (zh) 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
TW202019962A (zh) * 2018-07-10 2020-06-01 法商賽諾菲公司 標靶CD38及TGF-β的組合療法
US11401324B2 (en) 2018-08-30 2022-08-02 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
US11518792B2 (en) 2018-08-30 2022-12-06 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CA3124415A1 (en) * 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
EP3739588A1 (en) * 2019-05-13 2020-11-18 Koninklijke Philips N.V. Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk
CN120924491A (zh) 2019-06-21 2025-11-11 免疫生物公司 多链嵌合多肽和其用途
AU2021220870A1 (en) 2020-02-11 2022-08-04 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
WO2021163299A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Chromatography resin and uses thereof
CN115836087A (zh) 2020-04-29 2023-03-21 Hcw生物科技公司 抗cd26蛋白及其用途
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
US20220119513A1 (en) * 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
CN112940119B (zh) * 2021-04-26 2022-05-20 北京芳渟阳生生物科技有限公司 一种单克隆抗体及其与间充质干细胞外泌体的联合应用
AU2022294100A1 (en) 2021-06-18 2024-02-01 Genzyme Corporation Anti-tgf-beta antibody formulations and their use
WO2023019215A1 (en) 2021-08-11 2023-02-16 HCW Biologics, Inc. Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases
CN115707716A (zh) * 2021-08-18 2023-02-21 丹生医药技术(上海)有限公司 一种TGF-β/VEGF双功能抗体融合蛋白
US20230144192A1 (en) * 2021-11-01 2023-05-11 Genzyme Corporation Treatment of osteogenesis imperfecta
KR20250004747A (ko) 2022-04-13 2025-01-08 이뮤니티바이오, 인크. 생체 시계 유전자 장애의 치료에 사용하기 위한 다중-사슬 키메라 폴리펩티드
WO2023201311A1 (en) 2022-04-13 2023-10-19 HCW Biologics, Inc. Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder
CN115508565B (zh) * 2022-10-20 2024-11-15 成都医学院第一附属医院 Cilp1作为肾纤维化生物标志物的应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
CA2280957A1 (en) 1997-02-14 1998-08-20 Leslie Orgel Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
ZA988461B (en) 1997-09-18 1999-03-30 Idec Pharma Corp Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
EP1074563A1 (en) 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
US20020063763A1 (en) 2000-11-29 2002-05-30 Mantell David Allen Apparatus and method for removing air bubbles from an ink jet printhead
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
NZ554885A (en) 2002-12-31 2009-07-31 Altus Pharmaceuticals Inc Complexes of hgh crystals and protamine polymers
EP1620128A1 (en) 2003-04-30 2006-02-01 Genzyme Corporation Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
CN1961003B (zh) * 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
DE602005027461D1 (de) 2004-04-21 2011-05-26 Enobia Pharma Inc Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
WO2006086469A2 (en) 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
CA2711256C (en) 2008-01-03 2019-01-15 The Scripps Research Institute Antibody targeting through a modular recognition domain
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
EP2379600B2 (en) 2008-12-22 2020-10-14 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
US20120294868A1 (en) 2009-04-24 2012-11-22 Edwards James R Anti-tgf-beta induction of bone cell function and bone growth
CA3083324A1 (en) 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
SG10201602394QA (en) * 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
SG195253A1 (en) 2011-06-03 2013-12-30 Xoma Technology Ltd Antibodies specific for tgf-beta
MX358447B (es) 2011-06-13 2018-08-21 Abgenomics Cooeperatief U A Star Anticuerpos anti-psgl-1 y usos de los mismos.
CA2852874A1 (en) 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
EP2855527B1 (en) 2012-05-31 2018-08-01 Innate Pharma Tlr3 binding agents
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP2908913B1 (en) * 2012-10-17 2018-10-03 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
HUE046702T2 (hu) * 2013-03-20 2020-03-30 Genzyme Corp Eljárások üvegcsontbetegség kezelésére
HRP20251426T1 (hr) 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
WO2015095404A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancers using pd-1 axis binding antagonists and taxanes
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
US20170216401A1 (en) 2014-03-17 2017-08-03 Piotr Jachimczak Combination for use in a method of treating cancer
WO2016057933A1 (en) 2014-10-10 2016-04-14 Global Biopharma, Inc. Methods for treating and/or preventing a tumor growth, invasion and/or metastasis
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
TWI733661B (zh) * 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
EP3770171A1 (en) * 2015-04-03 2021-01-27 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
TN2017000440A1 (en) 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
JP2019533003A (ja) 2016-08-11 2019-11-14 プレシセラ，インコーポレイテッド ＴＧＦ−βアンタゴニストコンジュゲート
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
TWI788321B (zh) 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體

Also Published As

Publication number Publication date
AU2018209391B2 (en) 2024-08-15
SG11201906660TA (en) 2019-08-27
MX2019008551A (es) 2020-01-27
US20220195026A1 (en) 2022-06-23
US10766955B2 (en) 2020-09-08
TWI856437B (zh) 2024-09-21
IL323799A (en) 2025-12-01
CN110520441B8 (zh) 2024-07-09
TW201833135A (zh) 2018-09-16
JP7411832B2 (ja) 2024-01-11
CN117417939A8 (zh) 2024-07-12
DOP2019000191A (es) 2019-10-15
MA47311A (fr) 2019-11-27
NZ796440A (en) 2025-12-19
UY37575A (es) 2018-10-31
TW202506185A (zh) 2025-02-16
IL311866A (en) 2024-06-01
JP7844425B2 (ja) 2026-04-13
JP7213186B2 (ja) 2023-01-26
TW202313678A (zh) 2023-04-01
AU2018209391A1 (en) 2019-09-05
NZ756431A (en) 2025-03-28
US11242384B2 (en) 2022-02-08
IL268112B1 (en) 2025-05-01
CR20190375A (es) 2019-12-17
CA3050845A1 (en) 2018-07-26
IL311866B2 (en) 2026-03-01
US20200399358A1 (en) 2020-12-24
JP2020514310A (ja) 2020-05-21
CO2019008946A2 (es) 2019-09-30
IL268112A (en) 2019-09-26
JP2026036696A (ja) 2026-03-05
US20180244763A1 (en) 2018-08-30
US12049496B2 (en) 2024-07-30
IL268112B2 (en) 2025-09-01
ECSP19059553A (es) 2019-08-30
TWI787230B (zh) 2022-12-21
JP2024038040A (ja) 2024-03-19
CL2019002011A1 (es) 2019-11-22
US20250026821A1 (en) 2025-01-23
PH12019501635A1 (en) 2019-11-04
BR112019014787A2 (pt) 2020-02-27
CN117417939A (zh) 2024-01-19
CN110520441A (zh) 2019-11-29
PE20200734A1 (es) 2020-07-23
CN110520441B (zh) 2023-11-14
MY200751A (en) 2024-01-13
JP2023052376A (ja) 2023-04-11
AU2024264593A1 (en) 2024-12-05
IL311866B1 (en) 2025-11-01
MX2023002588A (es) 2023-03-22

Similar Documents

Publication Publication Date Title
ZA201904494B (en) Anti¿tgf¿beta antibodies and their use
ZA202006904B (en) Anti-il-4r antibody and use thereof
IL282968A (en) Anti-NKG2A antibodies and their use
ZA201901113B (en) Anti¿tim¿3 antibodies and use thereof
IL268206A (en) Antibodies directed against bcma and their use
IL276950A (en) Anti-CD73 antibodies and uses thereof
IL275737A (en) Variant antibodies against TIGIT
ZA201904619B (en) Anti¿cd73 antibodies and uses thereof
SG11202100746WA (en) Anti-tigit antibody and use thereof
ZA201900193B (en) Anti¿pd¿l1 antibodies and uses thereof
ZA202006066B (en) Anti-hla-g antibodies and use thereof
ZA201800352B (en) Anti¿angptl8 antibodies and uses thereof
ZA201801943B (en) Anti¿lag3 antibodies and uses thereof
IL275826A (en) Anti-mct1 antibodies and their uses
IL268506A (en) Antibody against human annexin a1
IL278466B1 (en) Anti-dll3 antibodies and uses thereof
IL282707A (en) Anti-tim-3 antibodies and their use
IL280321A (en) Antibodies against CXCR2 and their uses
ZA201806293B (en) New anti¿sirpa antibodies and their therapeutic applications
IL281202A (en) Anti-TNFRSF9 antibodies and uses thereof
IL282708A (en) Anti-tim-3 antibodies and their use
LT3445785T (lt) Humanizuoti anti clever-1 antikūnai ir jų naudojimas
IL277075A (en) Anti-PHF-tau antibodies and uses thereof
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
ZA201807132B (en) Humanized anti-basigin antibodies and the use thereof